3-[2-(4-methoxyphenyl)-2-oxoethoxy]-6H-benzo[c]chromen-6-one | 376612-05-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 3-[2-(4-methoxyphenyl)-2-oxoethoxy]-6H-benzo[c]chromen-6-one
• 英文别名: 3-[2-(4-methoxyphenyl)-2-oxoethoxy]benzo[c]chromen-6-one
• CAS: 376612-05-4
• 化学式: C₂₂H₁₆O₅
• mdl: MFCD02163980
• 分子量: 360.366
• InChiKey: NYQSZSGLYQYAOH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  27
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  61.8
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  3-[2-(4-methoxyphenyl)-2-oxoethoxy]-6H-benzo[c]chromen-6-one 在 sodium hydroxide 作用下， 以 异丙醇 为溶剂， 以88%的产率得到10-(4-methoxyphenyl)-5H-benzo[c]furo[3,2-g]chromen-5-one
  参考文献：
  名称：

  摘要：

  Substituted 5H-benzo[c]furo[3,2-g]chromen-5-ones, modified analogs of psoralen that contain a benzene ring annelated at the 5,6-position of a furo[3,2-g]chromen-7-one system were synthesized from 3-hydroxy-6H-benzo[c]chromen-6-ones.

  DOI：

  10.1023/a:1022103524800
• 作为产物：
  描述：

  尿石素B 、 alpha-溴-4-甲氧基苯乙酮 在 potassium carbonate 作用下， 以 丙酮 为溶剂， 以88%的产率得到3-[2-(4-methoxyphenyl)-2-oxoethoxy]-6H-benzo[c]chromen-6-one
  参考文献：
  名称：

  摘要：

  Substituted 5H-benzo[c]furo[3,2-g]chromen-5-ones, modified analogs of psoralen that contain a benzene ring annelated at the 5,6-position of a furo[3,2-g]chromen-7-one system were synthesized from 3-hydroxy-6H-benzo[c]chromen-6-ones.

  DOI：

  10.1023/a:1022103524800

文献信息

• Compositions and methods to treat skin diseases characterized by cellular proliferation and angiogenesis
  申请人：Sherris David

  公开号：US20060257337A1

  公开（公告）日：2006-11-16

  Described herein are compositions and methods for preventing and/or treating skin diseases including, but not limited to, psoriasis and atopic dermatitis as well as providing anti-aging benefits which results in reduced appearance of wrinkles and aged skin, improved skin color, treatment of photodamaged skin, improvement in skin's radiance and clarity and finish, and an overall healthy and youthful appearance of the skin, involving aberrant angiogenesis and hyperplasia employing one or more benzo[c]chromen-6-one derivatives.

  本文描述了一种预防和/或治疗皮肤疾病的组合物和方法，包括但不限于银屑病和特应性皮炎，以及提供抗衰老益处，减少皱纹和老化皮肤的出现，改善皮肤颜色，治疗光损伤皮肤，改善皮肤的光泽和清晰度以及完美度，以及使皮肤呈现整体健康和年轻外观，涉及使用一个或多个苯并[c]色素-6-酮衍生物的异常血管生成和增生。
• COMPOSITIONS AND METHODS TO TREAT DISEASES CHARACTERIZED BY CELLULAR PROLIFERATION AND ANGIOGENESIS
  申请人：Sherris I. David

  公开号：US20070197567A1

  公开（公告）日：2007-08-23

  Described herein are compositions and methods for preventing and/or treating diseases involving aberrant angiogenesis employing one or more benzo[c]chromen-6-one derivatives.

  本文描述了使用一种或多种苯并[c]色酮-6-酮衍生物预防和/或治疗涉及异常血管生成的疾病的组合物和方法。
• COMPOSITIONS AND METHODS TO TREAT SKIN DISEASES CHARACTERIZED BY CELLULAR PROLIFERATION AND ANGIOGENESIS
  申请人：SHERRIS David

  公开号：US20110268679A1

  公开（公告）日：2011-11-03

  Described herein are compositions and methods for preventing and/or treating skin diseases including, but not limited to, psoriasis and atopic dermatitis as well as providing anti-aging benefits which results in reduced appearance of wrinkles and aged skin, improved skin color, treatment of photodamaged skin, improvement in skin's radiance and clarity and finish, and an overall healthy and youthful appearance of the skin, involving aberrant angiogenesis and hyperplasia employing one or more benzo[c]chromen-6-one derivatives.

  本文描述了一种预防和/或治疗皮肤疾病的组合物和方法，包括但不限于银屑病和特应性皮炎，以及提供抗衰老效益，从而减少皱纹和老化皮肤的出现，改善皮肤颜色，治疗光损伤皮肤，改善皮肤的光泽度和清晰度，以及整体健康和年轻的外观，涉及异常血管生成和增生，并采用一种或多种苯并[c]色酮衍生物。
• COMPOSITIONS AND METHODS TO TREAT DISEASE CHARACTERIZED BY CELLULAR PROLIFERATION AND ANGIOGENESIS
  申请人：Paloma Pharmaceuticals, Inc.

  公开号：US20140105920A1

  公开（公告）日：2014-04-17

  Described herein are compositions and methods for preventing and/or treating diseases involving aberrant angiogenesis employing one or more benzo[c]chromen-6-one derivatives.

  本文描述了使用一种或多种苯并[c]色酮-6-酮衍生物预防和/或治疗涉及异常血管生成的疾病的组合物和方法。
• METHODS OF TREATING FIBROTIC DISORDERS
  申请人：Sherris David

  公开号：US20110021618A1

  公开（公告）日：2011-01-27

  Described herein are compositions and methods for preventing and/or treating fibrotic disorders employing one or more benzo[c]chromen-6-one derivatives.